Loading...
Market
How will Amylyx Pharmaceuticals' stock price react to the acquisition of Avexitide by August 31, 2024?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
NYSE official stock price data
Story
Amylyx Pharmaceuticals ($AMLX) Acquires Avexitide with FDA Breakthrough Therapy Designation
Jul 10, 2024, 11:04 AM
Amylyx Pharmaceuticals ($AMLX) has announced the acquisition of Avexitide, a Phase 3-ready GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation. The acquisition aims to bolster Amylyx's portfolio in blood sugar drugs, particularly for conditions such as hyperinsulinemic hypoglycemia, including post-bariatric surgery and congenital cases. The drug has supportive p2 data. The company plans to discuss the acquisition further in an upcoming conference call. The deal is seen as advantageous due to the current biotech bear market. The acquisition involves assets from Eiger ($EIGRQ).
View original story
Similar markets
Stock price increases by more than 10% • 25%
Stock price remains within +/- 10% range • 25%
Stock price decreases by more than 10% • 25%
Stock price fluctuates but ends within +/- 5% range • 25%
Increase by more than 5% • 25%
Decrease by more than 5% • 25%
Fluctuate within ±5% • 25%
No significant change • 25%
Below $200 • 25%
$200 to $250 • 25%
$250 to $300 • 25%
Above $300 • 25%
Yes • 50%
No • 50%
Stock price increases by more than 5% • 33%
Stock price remains within +/- 5% • 33%
Stock price decreases by more than 5% • 34%
Stock price above $50 • 25%
Stock price between $20 and $50 • 25%
Stock price between $5 and $20 • 25%
Stock price below $5 • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Decrease by less than 20% • 25%
Decrease by 20% or more • 25%
Stock price increases by more than 10% • 25%
Stock price increases by 0-10% • 25%
Stock price decreases by 0-10% • 25%
Stock price decreases by more than 10% • 25%